Abbott revenue misses as heart devices eclipse diabetes gains

(Reuters) - Abbott Laboratories fell just short of Wall Street estimates for quarterly revenue on Wednesday, as weakness in the medical device maker's cardiovascular business overshadowed strong performance in its fast-growing diabetes care unit.Shares of the company, which also trimmed its full-year profit forecast, flitted between gains and losses. They were last up about 1.7%, after having risen about 13% to Tuesday's close."In this environment, investors are nervous. Any room for..